PGP and ovarian carcinoma: Moreover, we describe the ability of silychristin and its 2,3-dehydro- derivative to inhibit P-glycoprotein (P-gp) and thus reverse the doxorubicin-resistance phenotype in resistant human ovarian carcinoma.